GlassScriptPhysician profile
Cassie Aline Bugay
NPI 1326716796
$4,598.15
in general payments reported to CMS, 2019-2025
50 companies · $2,189 in 2025
The $2,189 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $687 · 2024: $1,722 · 2025: $2,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,000 · Education: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,000.09 |
| Education | $598.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $307.67 | 2024-2025 | Padcev, Xtandi, Vyloy |
| Pfizer INC. | $279.59 | 2024-2025 | |
| Daiichi Sankyo INC. | $243.61 | 2023-2025 | Datroway, Enhertu, Injectafer |
| Astrazeneca Pharmaceuticals LP | $233.82 | 2023-2025 | Lynparza, Enhertu, Calquence |
| Janssen Biotech, INC. | $220.85 | 2023-2025 | Imbruvica, Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $219.31 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $214.34 | 2023-2025 | Ninlaro, Fruzaqla |
| Novartis Pharmaceuticals Corporation | $198.08 | 2024-2025 | |
| Myriad Genetic Laboratories, INC. | $186.74 | 2023 | Precisetumor |
| Regeneron Healthcare Solutions, INC. | $153.65 | 2024-2025 | Libtayo, Lynozyfic |
| Incyte Corporation | $141.93 | 2023-2025 | Jakafi, Monjuvi, Niktimvo |
| Genzyme Corporation | $134.78 | 2023-2025 | |
| Exelixis INC. | $118.24 | 2023-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $106.06 | 2024-2025 | |
| Stemline Therapeutics INC. | $103.50 | 2023-2025 | Orserdu |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $99.99 | 2025 | |
| Abbvie INC. | $99.88 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $99.40 | 2023-2025 | Zepzelca |
| Sanofi-Aventis U.S. LLC | $98.00 | 2024 | |
| Glaxosmithkline, LLC. | $82.57 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Genentech USA, INC. | $81.29 | 2023-2025 | Tecentriq, Polivy, Columvi |
| Lilly USA, LLC | $78.05 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Celgene Corporation | $74.33 | 2025 | Reblozyl |
| Beone Medicines USA, INC. | $67.70 | 2025 | Brukinsa |
| Coherus Oncology, INC. | $65.87 | 2023-2025 | Udenyca, Loqtorzi |
| Adaptive Biotechnologies Corporation | $64.95 | 2023-2024 | Clonoseq |
| Geron Corporation | $61.48 | 2025 | Rytelo |
| Servier Pharmaceuticals LLC | $60.51 | 2024-2025 | |
| Blueprint Medicines Corporation | $50.34 | 2024-2025 | Ayvakit |
| Karyopharm Therapeutics INC. | $48.18 | 2024 | Xpovio |
| Alexion Pharmaceuticals, INC. | $42.80 | 2024 | Ultomiris |
| Mirati Therapeutics, INC. | $41.98 | 2024 | Krazati |
| Pharmaessentia USA Corporation | $38.45 | 2025 | Besremi |
| Fresenius Kabi USA, LLC | $38.40 | 2025 | Stimufend |
| Puma Biotechnology, INC. | $38.13 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $37.45 | 2024-2025 | Onivyde |
| Agios Pharmaceuticals, INC. | $37.44 | 2025 | Pyrukynd |
| Eisai INC. | $37.22 | 2025 | |
| Aveo Pharmaceuticals, INC. | $34.90 | 2023-2024 | Fotivda |
| E.R. Squibb & Sons, L.L.C. | $34.16 | 2023 | Opdivo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.01 | 2024 | Gilotrif |
| Sun Pharmaceutical Industries INC. | $29.27 | 2023 | Yonsa |
| Immunogen, INC. | $26.26 | 2024 | Elahere |
| Tersera Therapeutics LLC | $22.75 | 2025 | Quzyttir |
| Caris Mpi, INC. | $22.40 | 2025 | Mi Cancer Seek |
| Sobi, INC | $20.65 | 2025 | |
| Acrotech Biopharma INC. | $18.72 | 2025 | Beleodaq |
| Array Biopharma INC | $18.41 | 2024-2025 | Mektovi, Tukysa, Braftovi |
| Rigel Pharmaceuticals, INC. | $17.77 | 2025 | Rezlidhia, Gavreto, Tavalisse |
| Organon LLC | $13.27 | 2025 | Ontruzant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassie Bugay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.